# SBRT Combined With Fruquintinib Plus PD-1/CTLA-4 Antibody for Third-line Treatment in mCRC

Source: https://onco.cc/trials/nct05747716/  
OnCo record `nct05747716` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial in colorectal cancer, run by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, not yet recruiting.

## Summary

SBRT Combined With Fruquintinib Plus PD-1/CTLA-4 Antibody for Third-line Treatment in mCRC is a phase 2, interventional study registered as NCT05747716 by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, with a registry enrolment figure of 44 participants, started 2023-02-28 and due to reach its primary completion in 2026-12-31. Interventions recorded: SBRT, Fruquintinib, Cadonilimab. Conditions listed: Metastatic Colorectal Cancer. Primary outcome: Progression free survival. Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT05747716
- Phase: 2
- Setting: SBRT Combined With Fruquintinib Plus PD-1/CTLA-4 Antibody Cadonilimab for Third-line Treatment in Metastatic Colonrectal Cancer.
- Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Enrolled: 44

## Sources

- ClinicalTrials.gov NCT05747716: https://clinicaltrials.gov/study/NCT05747716

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [SBRT / SABR (stereotactic radiotherapy)](https://onco.cc/technologies/sbrt/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05747716.json